Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 2
1976 2
1977 2
1979 2
1981 3
1982 3
1983 2
1984 13
1985 11
1986 13
1987 18
1988 15
1989 12
1990 15
1991 23
1992 14
1993 7
1994 16
1995 18
1996 14
1997 30
1998 10
1999 16
2000 36
2001 18
2002 26
2003 28
2004 27
2005 25
2006 24
2007 27
2008 35
2009 37
2010 38
2011 37
2012 30
2013 38
2014 48
2015 39
2016 26
2017 35
2018 29
2019 15
2020 21
2021 13
2022 8
2023 9
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

883 results

Results by year

Filters applied: . Clear all
Page 1
Bictegravir.
Spagnuolo V, Castagna A, Lazzarin A. Spagnuolo V, et al. Among authors: lazzarin a. Curr Opin HIV AIDS. 2018 Jul;13(4):326-333. doi: 10.1097/COH.0000000000000468. Curr Opin HIV AIDS. 2018. PMID: 29746268 Review.
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, Girard PM, Brar I, Daar ES, Wohl D, Rockstroh J, Wei X, Custodio J, White K, Martin H, Cheng A, Quirk E. Gallant J, et al. Among authors: lazzarin a. Lancet. 2017 Nov 4;390(10107):2063-2072. doi: 10.1016/S0140-6736(17)32299-7. Epub 2017 Aug 31. Lancet. 2017. PMID: 28867497 Clinical Trial.
Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials.
Sax PE, Arribas JR, Orkin C, Lazzarin A, Pozniak A, DeJesus E, Maggiolo F, Stellbrink HJ, Yazdanpanah Y, Acosta R, Huang H, Hindman JT, Martin H, Baeten JM, Wohl D; GS-US-380-1489 and GS-US-380-1490 study investigators. Sax PE, et al. Among authors: lazzarin a. EClinicalMedicine. 2023 May 11;59:101991. doi: 10.1016/j.eclinm.2023.101991. eCollection 2023 May. EClinicalMedicine. 2023. PMID: 37200995 Free PMC article.
A Mobile Application for Exercise Intervention in People Living with HIV.
Bonato M, Turrini F, DE Zan V, Meloni A, Plebani M, Brambilla E, Giordani A, Vitobello C, Caccia R, Piacentini MF, LA Torre A, Lazzarin A, Merati G, Galli L, Cinque P. Bonato M, et al. Among authors: lazzarin a. Med Sci Sports Exerc. 2020 Feb;52(2):425-433. doi: 10.1249/MSS.0000000000002125. Med Sci Sports Exerc. 2020. PMID: 31415448 Clinical Trial.
Biobanking for COVID-19 research.
Rovere-Querini P, Tresoldi C, Conte C, Ruggeri A, Ghezzi S, DE Lorenzo R, DI Filippo L, Farina N, Ramirez GA, Ripa M, Mancini N, Cantarelli E, Galli L, Poli A, DE Cobelli F, Bonini C, Manfredi AA, Franchini S, Spessot M, Carlucci M, Dagna L, Scarpellini P, Ambrosio A, DI Napoli D, Bosi E, Tresoldi M, Lazzarin A, Landoni G, Martino G, Zangrillo A, Poli G, Castagna A, Vicenzi E, Clementi M, Ciceri F; COVID-BioB Study Group. Rovere-Querini P, et al. Among authors: lazzarin a. Panminerva Med. 2022 Jun;64(2):244-252. doi: 10.23736/S0031-0808.20.04168-3. Epub 2020 Oct 19. Panminerva Med. 2022. PMID: 33073557
Relapse of Symptomatic Cerebrospinal Fluid HIV Escape.
Ferretti F, De Zan V, Gerevini S, Turrini F, Boeri E, Gianotti N, Hasson H, Lazzarin A, Cinque P. Ferretti F, et al. Among authors: lazzarin a. Curr HIV/AIDS Rep. 2020 Oct;17(5):522-528. doi: 10.1007/s11904-020-00526-x. Curr HIV/AIDS Rep. 2020. PMID: 32875516 Review.
Evaluation of HIV-DNA and residual viremia levels through week 96 in HIV-infected individuals who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor-based regimen.
Scutari R, Galli L, Alteri C, Poli A, Piermatteo L, Bigoloni A, Perno CF, Lazzarin A, Ceccherini-Silberstein F, Castagna A, Santoro MM, Gianotti N. Scutari R, et al. Among authors: lazzarin a. Int J Antimicrob Agents. 2023 May;61(5):106771. doi: 10.1016/j.ijantimicag.2023.106771. Epub 2023 Mar 3. Int J Antimicrob Agents. 2023. PMID: 36870403 Clinical Trial.
An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project.
Andreoni M, Marcotullio S, Puro V, De Carli G, Tambussi G, Nozza S, Gori A, Rusconi S, Santoro MM, Clementi M, Perno CF, d'Arminio Monforte A, Maggiolo F, Castagna A, De Luca A, Galli M, Giacomelli A, Borderi M, Guaraldi G, Calcagno A, Di Perri G, Bonora S, Mussini C, Di Biagio A, Puoti M, Bruno R, Zuccaro V, Antinori A, Cinque P, Croce D, Restelli U, Rizzardini G, Lazzarin A. Andreoni M, et al. Among authors: lazzarin a. New Microbiol. 2015 Oct;38(4):443-90. New Microbiol. 2015. PMID: 26571377 Free article. Review.
Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice.
Ranzenigo M, Gianotti N, Galli L, Poli A, Mastrangelo A, Bruzzesi E, Chiurlo M, Nozza S, Bossolasco S, Spagnuolo V, Mancusi D, Termini R, Carini E, Lazzarin A, Castagna A. Ranzenigo M, et al. Among authors: lazzarin a. Drug Des Devel Ther. 2022 Jun 27;16:1975-1982. doi: 10.2147/DDDT.S358976. eCollection 2022. Drug Des Devel Ther. 2022. PMID: 35783200 Free PMC article.
883 results